ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02482753
Recruitment Status : Active, not recruiting
First Posted : June 26, 2015
Last Update Posted : April 12, 2018
Sponsor:
Information provided by (Responsible Party):
Chipscreen Biosciences, Ltd.

Brief Summary:
This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Chidamide Drug: exemestane Drug: placebo Phase 3

Detailed Description:
This study including two parts: (1) Part A, open-label design, 20 patients will be enrolled and receive 30 mg Chidamide BIW and 25 mg exemestane QD. The main object of part A is to evaluate the pharmacokinetic and pharmacodynamic profile of Chidamide when in combination with exemestane. (2) Part B, randomized and double-blinded design, 328 patients will be assigned randomly in a 2:1 ratio to experiment group (30 mg Chidamide BIW + 25 mg exemestane QD) and control group (placebo BIW + 25 mg exemestane QD), to evaluate the efficacy and safety of Chidamide when in combination with exemestane in patients with locally advanced or metastatic estrogen receptor-positive breast cancer progressing on endocrine therapy.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 365 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)
Actual Study Start Date : July 2015
Actual Primary Completion Date : March 2018
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Exemestane

Arm Intervention/treatment
Experimental: Chidamide + exemestane, open-label
Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Chidamide
30 mg, administered orally twice per week (BIW)
Other Name: CS055

Drug: exemestane
25 mg, PO daily
Other Name: Aromasin

Experimental: Chidamide + exemestane, double-blinded
Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Chidamide
30 mg, administered orally twice per week (BIW)
Other Name: CS055

Drug: exemestane
25 mg, PO daily
Other Name: Aromasin

Placebo Comparator: placebo + exemestane, double-blinded
Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: exemestane
25 mg, PO daily
Other Name: Aromasin

Drug: placebo
Administered orally twice per week (BIW)
Other Name: Simulation tablet of Chidamide




Primary Outcome Measures :
  1. progression-free survival (PFS), double-blinded period [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years ]
    PFS is measured from the date of randomization until progression or death, whichever is first met

  2. pharmacokinetic profiles of Chidamide, open-label period [ Time Frame: 0,1,2,4,8,12,24,48,72 hours after the first dose of Chidamide on day 2 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage ]
    The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)

  3. pharmacokinetic profiles of exemestane, open-label period [ Time Frame: 0,1,2,4,8,12,24 hours after the first dose of exemestane on day 1 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage ]
    The pharmacokinetic parameters include Area under the plasma concentration versus time curve (AUC) , Peak Plasma Concentration (Cmax), time to reach Cmax (Tmax), mean concentration at steady state (Css)

  4. acetylation level of histone H3, open-label period [ Time Frame: pre-dose of Chidamide on day 2 at induced stage (4 days in total); pre-dose of Chidamide on day 1 of cycle 2 at combination treatment stage ]
    The acetylation level of histone H3 is assayed by enzyme-linked immuno sorbent assay (ELISA).


Secondary Outcome Measures :
  1. overall survival, double-blinded period [ Time Frame: Time from randomization to death from any cause, assessed up to 6 years ]
    OS is measured from the date of randomization until death

  2. duration of response (DOR), double-blinded period [ Time Frame: From the first date of response until the date of first documented progression, assessed up to 3years ]
    DOR is measured from the first date when criteria for response is met until the first date when the criteria for progression is met

  3. objective response rate (ORR), open-label period and double-blinded period [ Time Frame: Response is assessed once every 6 weeks, assessed up to 3 years ]
    ORR is defined as percentage of participants with Complete Response and Partial Response, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)

  4. clinical benefit rate (CBR), open-label period and double-blinded period [ Time Frame: Response is assessed once every 6 weeks, assessed up to 3 years ]
    ORR is defined as percentage of participants with Complete Response, Partial Response or Stable Disease ≥ 24 weeks, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)

  5. PFS, open-label period [ Time Frame: Time from the start of treatment to the earliest of documented disease progression, or death, assessed up to 3 years ]
    PFS is measured from the start of treatment until progression or death, whichever is first met



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 ~ 75 years old, postmenopausal women;
  2. Histological or cytological confirmation of hormone receptor-positive [estrogen receptor (ER) positive and progesterone receptors (PgR) positive or negative] breast cancer;
  3. Disease progression or recurrence after at least one endocrine therapy (either in advanced/metastatic setting or adjuvant setting);
  4. ≤4 prior therapies (either in advanced/metastatic setting or adjuvant setting), patients may have received one prior chemotherapy;
  5. The disease condition is inoperable, stage III or stage IV, at least one measurable lesion or simple bone metastases with no measurable lesions;
  6. Last prior therapy intervals: (a) if the last treatment was endocrine therapy, the interval must ≥ 2 weeks; (b) if the last treatment was chemotherapy therapy, the interval must ≥ 4 weeks;
  7. Eastern Cooperative Oncology Group Performance Status: 0~1;
  8. Absolute neutrophil count ≥ 1.5×109 / L, platelet count ≥ 100×109 / L, hemoglobin ≥ 90 g/L;
  9. Life expectancy ≥ 3 months;
  10. Have signed informed consent.

Exclusion Criteria:

  1. Patients have known central nervous system (CNS) metastases or a history of CNS metastases , or with leptomeningeal disease;
  2. Patients with human epidermal growth factor receptor-2 (Her-2) positive;
  3. Patients previously received treatment with exemestane;
  4. Patients received radiotherapy ≤ 4 weeks prior to study entry;
  5. Patients with no measurable lesion (except simple bone metastasis), such as pleural or pericardial effusion, ascites, et al;
  6. Patients have uncontrolled or significant cardiovascular disease, including:

    1. Myocardial infarction (< the last 12 months)
    2. Uncontrolled angina (< the last 6 months)
    3. Congestive heart failure (< the last 6 months), or Left Ventricular Ejection Fraction (LVEF) < 50% prior to study entry
    4. History of any significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or TdP)
    5. History of significant QT interval prolongation, or Corrected QT Interval (QTc) > 450 ms prior to study entry
    6. History of cerebrovascular accident
    7. Symptomatic coronary heart disease requiring treatment with agents
  7. The size of fluid area detected by cardiac ultrasonography in cavum pericardium is ≥10mm during diastolic period;
  8. History of organ transplantation;
  9. Patients have not recovered from all clinically relevant toxicities to grade 1 due to prior therapies;
  10. Patients have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would interfere the ingestion,transportation or absorption of oral agents;
  11. Active infection [Suffered from active infection of bacteria, virus, fungi, mycobacteria, parasites, or other infections (excluding nail bed fungal infections), or require intravenous antibiotic therapy, or antiviral therapy, or hospitalization due to any significant infection events], or persistent fever within 14 days prior to study entry;
  12. Patients had organ surgery < 6 weeks prior to study entry;
  13. Abnormal liver function [total bilirubin > 1.5×upper limit of normal (> 3×upper limit of normal in case of Gilbert syndrome); Transaminases (ALT, AST) >2.5×upper limit of normal (>5x upper limit of normal patients with liver metastases), abnormal renal function (serum creatinine > 1.5×upper limit of normal);
  14. Patients with prior invasive malignancies with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years;
  15. Any mental or cognitive disorder, that would interfere the ability to understand the informed consent document or the operation and compliance of study;
  16. Patients are currently enrolled in another investigational drug study, or completed within 4 weeks prior to study entry, with the exception of patients only in overall survival follow-up;
  17. Any other condition which is inappropriate for the study in the opinion of the investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02482753


Locations
China, Beijing
The 307th Hospital of Chinese people's Liberation Army
Beijing, Beijing, China, 100021
Sponsors and Collaborators
Chipscreen Biosciences, Ltd.
Investigators
Principal Investigator: Zefei Jiang 307 Hospital of PLA

Responsible Party: Chipscreen Biosciences, Ltd.
ClinicalTrials.gov Identifier: NCT02482753     History of Changes
Other Study ID Numbers: CDM301
First Posted: June 26, 2015    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Chipscreen Biosciences, Ltd.:
Chidamide
breast cancer
exemestane
Estrogen Receptor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Exemestane
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs